MX9603991A - Peptidos para inhibir la liberacion de pepsina. - Google Patents

Peptidos para inhibir la liberacion de pepsina.

Info

Publication number
MX9603991A
MX9603991A MX9603991A MX9603991A MX9603991A MX 9603991 A MX9603991 A MX 9603991A MX 9603991 A MX9603991 A MX 9603991A MX 9603991 A MX9603991 A MX 9603991A MX 9603991 A MX9603991 A MX 9603991A
Authority
MX
Mexico
Prior art keywords
pepsine
release
peptides
peptides inhibiting
inhibiting
Prior art date
Application number
MX9603991A
Other languages
English (en)
Other versions
MXPA96003991A (es
Inventor
Monique Descroix-Vagne
Danielle Pansu
Therry Tarrade
Original Assignee
Conseils De Rech S Et Soc D
Applic Scient D
Inst Nat Sante Et De
Rech Medicale Inserm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conseils De Rech S Et Soc D, Applic Scient D, Inst Nat Sante Et De, Rech Medicale Inserm filed Critical Conseils De Rech S Et Soc D
Publication of MX9603991A publication Critical patent/MX9603991A/es
Publication of MXPA96003991A publication Critical patent/MXPA96003991A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se refiere a péptidos derivados de la secuencia C-terminal de la sorbina, pero conteniendo cuando menos un residuo de aminoácido de configuracion D, los cuales inhiben la liberacion de pepsina y, por lo tanto, son particularmenteutiles en el tratamiento de ulceras o de esofagitis. La presente invencion también se refiere a las sales y derivados de sustitucion, así como a las composiciones farmacéuticas que contienen dichos péptidos.
MXPA/A/1996/003991A 1994-03-16 1996-09-10 Peptidos para inhibir la liberacion de pepsina MXPA96003991A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9405162.0 1994-03-16
GB9405162A GB9405162D0 (en) 1994-03-16 1994-03-16 Heptapeptides
PCT/FR1995/000296 WO1995025123A1 (fr) 1994-03-16 1995-03-14 Peptides pour inhiber la liberation de pepsine

Publications (2)

Publication Number Publication Date
MX9603991A true MX9603991A (es) 1997-09-30
MXPA96003991A MXPA96003991A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
NO316802B1 (no) 2004-05-18
GB9504733D0 (en) 1995-04-26
BR9507063A (pt) 1997-09-02
CA2144569A1 (en) 1995-09-17
ES2127516T3 (es) 1999-04-16
FR2717390A1 (fr) 1995-09-22
FR2717391B1 (fr) 1996-05-31
PL180672B1 (pl) 2001-03-30
TNSN95019A1 (fr) 1996-02-06
GB9405162D0 (en) 1994-04-27
JPH09512787A (ja) 1997-12-22
KR100359713B1 (ko) 2003-01-15
RO112729B1 (ro) 1997-12-30
FI963615A0 (fi) 1996-09-13
DE69506390D1 (de) 1999-01-14
KR970701732A (ko) 1997-04-12
IE950192A1 (en) 1995-09-20
DZ1865A1 (fr) 2002-02-17
JP3109835B2 (ja) 2000-11-20
NZ270704A (en) 1996-05-28
AP9500724A0 (en) 1995-04-30
FR2717390B1 (fr) 1996-05-31
AU694476B2 (en) 1998-07-23
DE69506390T2 (de) 1999-07-01
GB2287942A (en) 1995-10-04
GR3029513T3 (en) 1999-05-28
MA23481A1 (fr) 1995-10-01
DK0750635T3 (da) 1999-08-16
US5668109A (en) 1997-09-16
FI963615A (fi) 1996-09-13
RU2144038C1 (ru) 2000-01-10
AU1487095A (en) 1995-09-28
FR2717391A1 (fr) 1995-09-22
OA10136A (fr) 1996-12-18
ZA951923B (es) 1995-12-11
AP546A (en) 1996-10-29
NO963856L (no) 1996-09-13
ATE174037T1 (de) 1998-12-15
NO963856D0 (no) 1996-09-13
CN1143968A (zh) 1997-02-26
CN1070865C (zh) 2001-09-12
WO1995025123A1 (fr) 1995-09-21
GB2287942B (en) 1997-07-16
EP0750635B1 (fr) 1998-12-02
UA55369C2 (uk) 2003-04-15
TW380141B (en) 2000-01-21
EP0750635A1 (fr) 1997-01-02
PL316288A1 (en) 1997-01-06

Similar Documents

Publication Publication Date Title
EP0528858A4 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
NZ296479A (en) Amino acid or peptide derivatives which are inhibitors of multicatalytic protease (mcp)
AU559914B2 (en) Peptide compounds
AU5669398A (en) Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them
NO992463D0 (no) N-(aryl/heteroarylacetyl)aminosyreestere, farmas°ytiske sammensetninger som omfatter det samme, og metoder for inhibering av <beta>-amyloidpeptidfrigivelse og/eller dens syntese ved bruk av slike forbindelser
AU2001290837A1 (en) Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
MX9500072A (es) Compuestos con propiedades de liberacion de la hormona del crecimiento.
AU5242000A (en) Nematicidal trifluorobutenes
IL109901A0 (en) Peptidic phosphinyloxymethyl ketones and pharmaceutical compositions containing them
MX9700557A (es) Dihidrobenzofuranos.
EP0301570A3 (en) Oligopeptides useful for treating aids
AU4710499A (en) Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use ofsuch compounds
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
DK0728148T3 (da) Forbedrede immunogene sammensætninger mod humant gastrin 17
ES2000852A6 (es) Un nuevo procedimiento para preparar intermediarios con residuos de acido 5-amino-2,5-disustituido -4- hidroxipentanoico,utiles en la sintesis de polipeptidos inhibidores de renina.
YU41199A (sh) Hinoksalindioni
TW268937B (es)
EP0830456A4 (en) ISOLATED PROTEIN B NUCLEIC ACID MOLECULE REGULATED BY Fe (FrpB) AND VACCINE USING THE SAME
AU5585198A (en) N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and ethods for inhibiting beta-amyloid peptide release and/or its synthesis
PL329413A1 (en) Chemical compounds exhibiting properties capable to cause growth hormone release
AU8748198A (en) Carcinostatic agents
MY117934A (en) Process for the preparation of n-methyl-3-(1-methyl-4- piperidinyl)-1h-indole-5-ethanesulphonamide
MX9603991A (es) Peptidos para inhibir la liberacion de pepsina.
NZ511618A (en) Kininogen fragment 2 peptides with the formula of at least X-His-Lys-X-Lys-X
AU3494093A (en) S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees